Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Cash & Equivalents (2020 - 2025)

IceCure Medical (ICCM) has disclosed Cash & Equivalents for 6 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 17.62% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 17.62% year-over-year, with the annual reading at $8.9 million for FY2025, 17.62% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $8.9 million at IceCure Medical, up from $7.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $25.6 million in Q4 2021, with the low at $7.6 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $15.3 million, with a median of $10.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 631.61% in 2021, then crashed 55.48% in 2023.
  • Over 5 years, Cash & Equivalents stood at $25.6 million in 2021, then dropped by 7.66% to $23.7 million in 2022, then crashed by 55.48% to $10.5 million in 2023, then fell by 28.19% to $7.6 million in 2024, then increased by 17.62% to $8.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $8.9 million, $7.6 million, and $10.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.